Broad Patient Adoption And Global Expansion Will Open Long-Term Opportunities
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
27 May 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$73.88
27.3% undervalued intrinsic discount15 Aug
US$53.70
1Y
104.7%7D
4.6%